is it time to buy ???
aTyr Pharma (NASDAQ:LIFE) Receives Average Rating of “Buy” from Brokerages
Posted by Stephan Byrd on Mar 3rd, 2016 // No Comments
hares of aTyr Pharma (NASDAQ:LIFE) have been assigned a consensus recommendation of “Buy” from the five research firms that are presently covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $42.00.
Several analysts recently weighed in on LIFE shares. Citigroup Inc. started coverage on aTyr Pharma in a research note on Wednesday, December 16th. They set a “neutral” rating for the company. JPMorgan Chase & Co. restated an “overweight” rating on shares of aTyr Pharma in a research note on Thursday, January 14th.
aTyr Pharma (NASDAQ:LIFE) traded down 3.524% on Thursday, hitting $5.065. The stock had a trading volume of 66,539 shares. aTyr Pharma has a 1-year low of $3.50 and a 1-year high of $28.29. The firm’s 50-day moving average price is $4.98 and its 200-day moving average price is $9.94. The firm’s market cap is $119.78 million.
aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using a set of physiological modulators. The Company has discovered approximately 300 Physiocrines, a class of naturally occurring proteins that promotes homeostasis.